Two-trigger drugs target 'zombie' cancer cells with sharper aim

Cancer treatments like chemotherapy aim to stop cancer cells from dividing, but this does not always make these cells harmless. Some cancer cells enter a state called senescence, where they stop dividing but remain alive. These 'zombie' cancer cells can secrete inflammatory signals that may encourage tumors to resist further treatment.

Researchers are developing drugs designed to target and kill these senescent cancer cells. Such drugs are called senolytics. The goal is to remove these harmful cells to improve cancer treatment outcomes.

How do these new drugs work?

Traditional drugs that kill senescent cells can also harm normal, healthy cells, leading to side effects. The new approach uses drugs that require two triggers before they become active. This double-trigger mechanism aims to sharpen the targeting specifically toward senescent cancer cells, potentially reducing collateral damage to normal tissues.

Evidence and current status

The available information highlights laboratory efforts focused on developing and testing these two-trigger drugs. There is no reported data yet from animal or human trials in the source material, so it remains uncertain how effective or safe these drugs will be in patients.

Limitations and unknowns

It is important to note that the 'two-trigger' strategy is still experimental. No evidence from human studies currently supports their use. Potential harms and the balance between benefits and risks are not yet fully understood. Moreover, while targeting senescent cells may seem promising, it is not yet proven that removing them definitively improves cancer outcomes.

Possible implications

If successful, this approach could complement existing cancer therapies by cleaning up harmful senescent cells that contribute to resistance and inflammation. This might reduce tumor regrowth or metastasis. However, more research is needed before these drugs could become available for patient use.

Source: Medical Xpress